Zander et al. have shown that 6 weeks of continuous subcutaneous GLP-1 infusion in patients with type 2 diabetes resulted in significant reductions in fasting and post-prandial NEFA levels [20]. This evidence concerns the gene GCG and type 2 diabetes mellitus.